COUMADIN 6 MG

国: イスラエル

言語: 英語

ソース: Ministry of Health

有効成分:

WARFARIN SODIUM

から入手可能:

TARO PHARMACEUTICAL INDUSTRIES LTD

ATCコード:

B01AA03

医薬品形態:

TABLETS

構図:

WARFARIN SODIUM 6 MG

投与経路:

PER OS

処方タイプ:

Required

製:

TARO PHARMACEUTICAL INDUSTRIES LTD

治療群:

WARFARIN

治療領域:

WARFARIN

適応症:

Coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonar embolis. Coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

承認日:

2023-06-30

製品の特徴

Final Physician Leaflet 08.2020
1
PRESCRIBING INFORMATION
COUMADIN TABLETS
1. NAME OF THE MEDICINAL PRODUCT
COUMADIN 1 mg
COUMADIN 2 mg
COUMADIN 2.5 mg
COUMADIN 5 mg
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet of Coumadin 1 mg contains 1 mg warfarin sodium.
Each tablet of Coumadin 2 mg contains 2 mg warfarin sodium.
Each tablet of Coumadin 2.5 mg contains 2.5 mg warfarin sodium.
Each tablet of Coumadin 5 mg contains 5 mg warfarin sodium.
For excipients, see 6.1.
3. PHARMACEUTICAL FORM
Tablets.
Presentation:
COUMADIN 1 mg tablets are pink, flat capsule shaped, beveled tablets,
one side engraved
with “WARFARIN” and "TARO", and other side scored and engraved
with “1”.
COUMADIN 2 mg tablets are lavender, flat capsule shaped, beveled
tablets, one side
engraved with “WARFARIN” and "TARO", and other side scored and
engraved with “2”.
COUMADIN 2.5 mg tablets are green, flat capsule shaped, beveled
tablets, one side
engraved with “WARFARIN” and "TARO", and other side scored and
engraved with “2½”.
COUMADIN 5 mg tablets are peach, flat capsule shaped, beveled tablets,
one side engraved
with “WARFARIN” and "TARO", and other side scored and engraved
with “5”.
The tablet can be divided into equal halves.
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
COUMADIN is indicated for the prophylaxis and/or treatment of venous
thrombosis and its
extension, and pulmonary embolism.
COUMADIN is indicated for the prophylaxis and/or treatment of the
thromboembolic
complications associated with atrial fibrillation and/or cardiac valve
replacement.
COUMADIN is indicated to reduce the risk of death, recurrent
myocardial infarction, and
thromboembolic events such as stroke or systemic embolization after
myocardial infarction.
Final Physician Leaflet 08.2020
2
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
The dosage and administration of COUMADIN must be individualized for
each patient
according to the particular patient's PT/INR response to the drug. The
dosage should be
adjusted based upon the pat